
AnaptysBio, Inc.: updates and filings
Price
$47.40
November 19, 2026Market cap $1.4B
What Ploutos Investor adds for AnaptysBio
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from 2015
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 5, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operationsForm8-K
- Sep 21, 2026Filingfor the period to Jun 30, 2026Form10-KT
- Sep 21, 2026Financial statements and exhibitsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Shareholder voteForm8-K
- Jul 30, 2026Regulation FD disclosureForm8-K
- Jun 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Jun 29, 2026Additional annual meeting materialFormDEFA14A
- Jun 29, 2026Annual meeting proxy statementFormDEF 14A
- Jun 22, 2026Material agreement enteredForm8-K
- May 29, 2026Regulation FD disclosureForm8-K
- May 21, 2026Amended articles or bylawsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operationsForm8-K
- May 11, 2026Officer or director changeForm8-K
- Apr 28, 2026Annual report (amendment)for the period to Dec 31, 2025Form10-K/A
- Apr 24, 2026Financial statements and exhibits (amendment)Form8-K/A
- Apr 20, 2026Material agreement entered, acquisition or disposal of assets, officer or director change, other material eventsForm8-K
- Mar 27, 2026Material agreement entered, material agreement ended, officer or director change, Regulation FD disclosureForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Sep 21, 2026 | 10-KT | Filingfor the period to Jun 30, 2026 | Document |
| Sep 21, 2026 | 8-K | Financial statements and exhibits | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | 8-K | Shareholder vote | Document |
| Jul 30, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Jun 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Jun 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Jun 22, 2026 | 8-K | Material agreement entered | Document |
| May 29, 2026 | 8-K | Regulation FD disclosure | Document |
| May 21, 2026 | 8-K | Amended articles or bylaws | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| May 11, 2026 | 8-K | Officer or director change | Document |
| Apr 28, 2026 | 10-K/A | Annual report (amendment)for the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | 8-K/A | Financial statements and exhibits (amendment) | Document |
| Apr 20, 2026 | 8-K | Material agreement entered, acquisition or disposal of assets, officer or director change, other material events | Document |
| Mar 27, 2026 | 8-K | Material agreement entered, material agreement ended, officer or director change, Regulation FD disclosure | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 6, 2006.
The full analysis
What do AnaptysBio's filings show?
The filings are where every one of AnaptysBio's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.